Cited 0 times in
성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 구자승 | - |
dc.contributor.author | 김승일 | - |
dc.contributor.author | 박병우 | - |
dc.contributor.author | 박세호 | - |
dc.contributor.author | 손주혁 | - |
dc.date.accessioned | 2016-02-04T11:29:37Z | - |
dc.date.available | 2016-02-04T11:29:37Z | - |
dc.date.issued | 2015 | - |
dc.identifier.issn | 1738-8082 | - |
dc.identifier.uri | https://ir.ymlib.yonsei.ac.kr/handle/22282913/140547 | - |
dc.description.abstract | Purpose: This study aimed to compare expression of human epidermal growth factor receptor (HER) family and insulin-like growth factor-1 receptor (IGF-1R) before and after targeted therapy in HER-2 positive breast cancers. Methods: Epidermal growth factor receptor (EGFR), HER-3, HER-4, and IGF-1R were immunohistochemically determined using pairwise archives tumor blocks of 28 patients received chemotherapy and HER-2 directed therapy between January 2007 and December 2011. Of them, 5 good responders achieved a pathologic complete response after neoadjuvant therapy and 23 poor responders experienced disease progression or metastasis even HER-2 targeted therapy. Expression of biomarkers was compared using chi-square test. Results: Stage II, III, and IV was 14 (50.0%), 11 (39.3%), and 3 (10.7%) patients, respectively. Hormone receptors-positive tumors were 15 (53.6%) patients and 9 (32.1%) patients received tyrosine kinase inhibitors with or without trastuzumab. Positive expression of initial EGFR, HER-3, HER-4, and IGF-1R was determined in 15 (53.6%), 11 (39.3%), 22 (78.6%), and 14 (50.0%) patients, respectively. Although there was no statistical significance, good responders showed a higher proportion of positive HER-3 expression. Among 23 poor responders, growth factor receptors family expression showed a trend of concordant results, however, unpredictively certain patients demonstrated discordant results between before and after targeted therapy. Conclusion: Unpredicted correlation of growth factor receptors family expression suggested that complex and personalized resistance mechanisms may be involved to HER-2 directed therapy. However, HER-3 expression might be associated with responsiveness to HER-2 targeted therapy. It would be important to develop diagnostic and therapeutic strategies for overcoming resistance to HER-2 targeted therapy. | - |
dc.description.statementOfResponsibility | open | - |
dc.format.extent | 12~19 | - |
dc.relation.isPartOf | Korean Journal of Clinical Oncology (대한임상종양학회지) | - |
dc.rights | CC BY-NC-ND 2.0 KR | - |
dc.rights.uri | https://creativecommons.org/licenses/by-nc-nd/2.0/kr/ | - |
dc.title | 성장인자수용체-2 양성 유방암 조직에서 표적치료 전후의 성장인자수용체군 발현양상 | - |
dc.title.alternative | Expression of growth factor receptor family before and after targeted therapy in human epidermal growth factor receptor-2 positive breast cancer tissues | - |
dc.type | Article | - |
dc.contributor.college | College of Medicine (의과대학) | - |
dc.contributor.department | Dept. of Internal Medicine (내과학) | - |
dc.contributor.googleauthor | 박세호 | - |
dc.contributor.googleauthor | 고영신 | - |
dc.contributor.googleauthor | 구자승 | - |
dc.contributor.googleauthor | 손주혁 | - |
dc.contributor.googleauthor | 김승일 | - |
dc.contributor.googleauthor | 박병우 | - |
dc.identifier.doi | 10.14216/kjco.15003 | - |
dc.admin.author | false | - |
dc.admin.mapping | false | - |
dc.contributor.localId | A00198 | - |
dc.contributor.localId | A00658 | - |
dc.contributor.localId | A01475 | - |
dc.contributor.localId | A01524 | - |
dc.contributor.localId | A01995 | - |
dc.relation.journalcode | J01986 | - |
dc.subject.keyword | Breast neoplasm | - |
dc.subject.keyword | Drug resistance | - |
dc.subject.keyword | Epidermal growth factor receptor | - |
dc.subject.keyword | Insulin like growth factor I receptor | - |
dc.subject.keyword | Molecular targeted therapy | - |
dc.contributor.alternativeName | Koo, Ja Seung | - |
dc.contributor.alternativeName | Kim, Seung Il | - |
dc.contributor.alternativeName | Park, Byeong Woo | - |
dc.contributor.alternativeName | Park, Se Ho | - |
dc.contributor.alternativeName | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | Koo, Ja Seung | - |
dc.contributor.affiliatedAuthor | Kim, Seung Il | - |
dc.contributor.affiliatedAuthor | Park, Byeong Woo | - |
dc.contributor.affiliatedAuthor | Park, Se Ho | - |
dc.contributor.affiliatedAuthor | Sohn, Joo Hyuk | - |
dc.contributor.affiliatedAuthor | 구자승 | - |
dc.rights.accessRights | free | - |
dc.citation.volume | 11 | - |
dc.citation.number | 1 | - |
dc.citation.startPage | 12 | - |
dc.citation.endPage | 19 | - |
dc.identifier.bibliographicCitation | Korean Journal of Clinical Oncology (대한임상종양학회지), Vol.11(1) : 12-19, 2015 | - |
dc.identifier.rimsid | 30164 | - |
dc.type.rims | ART | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.